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The Agricultural & Environmental 
Diagnostic Market 
• The global market for analytical testing 
associated with the water and environmental 
industries was estimated in 2009 to be $1.4 
billion. 
• The overall growth rate in developed markets 
is estimated at 2 to 3%. 
• The overall growth rate in BRICKs countries, 
primarily Asia, is estimated at 7 to 9%. 
• Driver for growth: governement regulations. 
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Overview of Non-Clinical Diagnostic Market, Brocair Partners, 2009. 
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The Agricultural & Environmental 
Market 
• The US market for food (& feed) safety testing 
in 2009, was worth $3.3 billion. 
• In 2017, the market should reach 
approximately $4.4 billion after a 5 year CAGR 
of 5.6%. 
• Market van be broken down by type of target: 
pathogens ($3.9 billion), GMO ($167 mio), 
toxins ($162 mio) and residues ($140 mio). 
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The Agricultural & Environmental 
Market 
• The Global Agricultural and Environmental 
diagnostic market will reach $3.8 billion by 2017 
according to Global Industry Analysts Inc. 
• Rapid and reliable testing methods are expected 
to capture more market share. 
• Mayor players: Biocontrol Systems, Biomerieux, 
Charm Sciences, Eurofins Scientific, IDEXX, 
Neogen, R-Biopharm, Vicam, 3M, etc. 
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Agricultural & Environmental Diagnostics, Global Industry Analysts, 2011. 
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Innovation and  
Intellectual Property (IP) 
• Creativity is the base of innovation and leads to 
economic value and competitive advantages. 
• Through the proper use of intellectual property, 
one has a much better chance of transforming 
creativity into economic value. 
• Intellectual property law recognizes a creator’s 
rights in ideas, creations, innovations, and 
goodwill. 
• Intellectual property differs from real property 
(land) or personal property (your possessions). 
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IP rights with a certificate 
9 
Patents 
 
Duration: 20 years 
Utility models 
 
Duration: max 10 years 
Trademarks 
 
Duration: 10 years or life 
Designs 
 
Duration: 5 x 5 years 
® 
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IP rights without a certificate 
10 
Copyright 
 
Literature; Pieces of music; 
Paintings; Drawings; Films; 
Construction works and scientific 
and technical representations 
 
The right will be in force min. 50 
years after the death of the 
originator (EU 70 years) 
Trademarks 
 
Unregistered 
Designs 
 
Unregistered 
Database right 
 
Databases that show originality in 
its selection, coordination and 
arrangement, automatic right, no 
registration 
 
Term: 15 years 
© 
TM 
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Some (non patent) Examples 
11 
Design #: 000158803-0001 
Merial Ltd. (29/3/2004) 
oami.europa.eu: 136 entries for registered  “pipette “designs 
Design #: 000203799-0001 
Heathrow Scientific LLC. (14/7/2004) 
Design #: 001065700-0001 
Gilson Sas (5/1/2009) 
www.uspto.gov: 37 entries for registered  “pipette” trade marks 
Trade Mark #: 85610923 
Apricot Designs Inc. (25/12/2012) 
Trade Mark #: 79018385 
Gilson Inc. (14/10/2012) 
Trade Mark #: 79018385 
Precision Pipette Inc. (12/3/2002) 
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VERY IMPORTANT! 
12 
• First think about possible new intellectual property and the 
protection thereof. 
• Before actually publishing or sharing information with third parties. 
• Also an invoice counts as prior art (use a MTA before applying for a 
patent). 
• If not all IP rights will/can be lost. 
YES NO 
Evaluate data or ideas for 
new IP and protect it 
 
Publish new data and ideas 
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Prior Art Search & Data Mining 
• Patents: www.wipo.int, www.uspto.gov, www.epo.org, espacenet.com, 
www.google.com/patents, ThomsonInnovation.com (pay site), 
www.pat2pdf.com, www.micropat.com (pay site), www.jpo.go.jp, 
www.jipo.cn, www.pctgazette.wipo.int, wipsglobal.com. 
 
• Trademarks and related items: www.uspto.gov, oami.europe.eu, 
www.register.boip.int, www.wipo.int/madrid/en, www.cpvr.info, 
ec.europa.eu/agriculture/quality/index_en.htm, 
icann.org/registrars/accredited_list.html, www.eurid.eu,  
oami.europa.eu. 
 
• Copyright: internet search engines, books, journals, magazines, flyers, 
brochures, www.sabam.be, www.guefa.de, www.copyright.gov, 
www.escroweurope.com, www.boip.int. 
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What can be patented? 
14 
YES 
 
1. A product 
2. The apparatus for producing the product 
3. The process for producing the product 
4. The use of the product 
NO 
 
1. Computer programs 
2. Medical and surgical treatments 
3. Mathematical methods 
4. Business methods 
5. Discoveries 
6. Aesthetic creations 
7. New species of plant or animal 
8. Inventions which are contrary to 
moral standards and public order 
(e.g. instruments of torture) 
9. The human body and any non-
separate part(s) thereof 
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Recent Important Changes 
• On September 16, President Obama signed the 
“America Invents Act” 
-rolled out in 2012, 2013 – 2014 
-”first inventor to file” (cfr. Europe) 
• On December 15, 2012, the EU signed the 
“European Unitary Patent” agreement 
-less expensive (less translations) 
-in English, German or French 
-Spain & Italy not participating (no Spanish or Italian) 
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Patenting Analytical Methods? 
• Could be possible since it is a process with an 
industrial value e.g. for CRO as a service. 
• After a patent has been filed, it will be 
published. 
• How can one police this IP? – very difficult. 
• Instead of filing for a patent, it could be better  
to keep it as a trade secret: no publication, no 
cost and not limited in time (as long as it is 
kept secret). 
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Valorization of IP  
18 
• A return needs to be created on 
new IP 
• Karl Marx first introduced the 
term valorization in his work 
“Das Kapital” 
• Original word used was 
“Kapitalverwertung”: the use or 
application of something so that 
it generates value 
• It is important that a surplus 
value is created 
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Valorization of IP 
• This can be done via different valorization 
routes/processes: 
– Develop the new IP into an article of commerce that can 
be sold 
– Out license the IP to another person or company 
– A new company e.g. a JV can be established 
– Not to render the new IP into an article to maintain the 
value of an existing business 
 
 The management of the valorization of new IP is actually 
Business Development. This includes identifying and 
evaluating a possible business, and then realizing its full 
potential, full value. 
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Valorization of IP 
• Not all new IP can generate value and a lot of new technologies or 
products fail 
• Germeraad et al.: 
– Over a 10 year period (1991-2000) more than US$ 200 billion invested in R&D 
at US universities 
– Resulted in 100 000 new patent disclosure 
– 50% were submitted for patent application 
– This yielded eventually 25 000 licenses and in the formation of 2 500 startup 
companies 
– Only 125 licenses that generate more than US$ 1 million per annum 
– Most of the licenses just bring in US$ 10 000 cumulatively 
 Sad return on investment 
 
Baggott, S.; Germeraad, P.; Khan, R.; Oliver, W.; Peregrim, J.; Wandji, S.A, Les Nouvelles, 2008, 261-271. 
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IP Valuation 
• Would it be lucrative to start this project? 
• Is there a market for this? 
• How much is new IP worth? 
• In case of licensing: what terms & conditions? 
 
 Questions that need to be answered before creating value on the 
new IP 
 
• There are many techniques for valuation 
• In this presentation we want to look at 2 different approaches: 
1. Using industrial standards 
2. Financial valuation via discounted cash flow methods 
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Industrial Standards 
• Most likely, historical data exists on previous done deals 
in a specific industrial sector for a specific type of 
technology or product 
– Established general terms & conditions (industry 
norms) 
– Business development literature 
– Business development communities 
– Databases (often pay) 
– Published agreements 
– Court cases 
23 
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Industrial Standards 
Example of a Court Case: 
• Innogentics filed a patent in 1993 on hepatitis C genotyping. 
• The patent was granted on December 8, 1998 (US5846704) 
• Abbott was infringing the patent according to the decision of 
The Court in 2006 (Fed.Lir. 2008): 
-mayor companies had taken a license on the patent (i.e. non 
exclusive). 
-$7 mio in damages to be paid by Abbott, including $5.8 mio 
market entry fee and an ongoing royalty of €5 to €10 per test. 
  
24 
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Established Industry Norms 
• Easy approach requiring less effort 
• Key is to have recent studies since the established 
norms can evolve over time 
• Journals where information can be found: 
– Les Nouvelles 
– Licensing Economics Review 
– Journal of the Association of University Technology 
Managers 
– Review of Financial Economics 
– International Review of Economics and Finance 
25 
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Established Industry Norms 
26 
Royalty rates dd. 2002 for different industries according to Muelhern et al. 
 
 
 
 
 
 
 
 
 
 
 
Muelhern, C.; Jaroz, J.; Goldschneider, R., Les Nouvelles, 2002, 123. 
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Established Industry Norms 
27 
Royalty rates according to Weinstein et al. dd. 2008 
 
 
 
Weinstein, R.; Mills, R.; Porter, M., Les Nouvelles, 2008, 47. 
•Variation over time 
•Significant differences between sectors: cfr. different 
margins 
•Differences between low and high return in a sector: 
cfr. stage of development, negotiation skills 
 
Industry Number of 
observations 
Average 
royalty rate 
(+) / (-) Lower 
bound 
Upper 
bound 
Medical device 77 4.35% 0.64% 3.71% 5.00% 
Pharmaceutical 90 5.66% 0.91% 4.75% 6.57% 
Chemical 21 3.70% 0.88% 2.82% 4.57% 
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Established Industry Norms 
• The royalty rate is important 
• Also important to evaluate different stage payments: 
– Upfront payment i.e. after signing the agreement 
– Various payments when a critical milestone has 
been reached or payment when a certain 
milestone in sales has been reached 
• Licensors prefer higher stage payments and lower 
royalties 
• Licensees prefer to agree on low stage payments and 
perhaps somewhat higher royalties 
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Historical Data on Deals 
• More reliable for deal making can be the study of available 
historical data on relevant past deals 
• The data needs to be for a similar product or technology for 
a similar industrial sector 
• This can be purchased from: 
– RoyaltyStat 
– Recap 
– Pharmadeals 
– Datamonitor 
– Life Science Analytics (www.medtrack.com) 
• This is often expensive 
• Also: your own (company/institute/person) experience & 
data – much cheaper 
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Historical Data on Deals 
30 
Ghent University developed new technology related to 
mycotoxin testing and closed an agreement with an 
industrial partner for commercialization. 
Mycotoxin Diagnostic Deal Terms 
Stage Fully developed 
IP Patent & know how for the production of antibodies 
Territory Worldwide 
Type Non exclusive for production & commercialization 
Stage payments Not included 
Duration 10 years, option to renew 
Royalties 10%  on Net sales up to $250000 
9% on Net Sales up between $250001 and $500000 
8% on Net Sales above $500001 
Other University to produce the antibody for Licensee @COGS + % 
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Historical Data on Deals 
31 
Ghent University developed new technology related to 
food safety modeling software and closed an agreement 
with an industrial partner for commercialization. 
Food Safety Software Deal Terms 
Stage Fully developed 
IP Software (©), Databases, Trademark,  
Territory worldwide 
Type Exclusive, for all IP and its commercialization 
Stage payments If sales reach €1 mio  €50000 
If sales reach €5 mio  €200000  
Duration 10 years, afterwards all rights will go to licensee  
Royalties 7%  on Net Sales 
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Historical Data on Deals 
• Under the rules of the Securities and Exchange Commission (SEC) of 
the US, public companies are required to disclose transactions with 
a significant effect on the value of the company, e.g. license 
agreements 
• Such agreements are filed and available to the public (cfr. 
www.SEC.gov) 
• SEC is also a great source to find more information on mergers and 
acquisition or on the value of goodwill 
– Goodwill is an intangible asset which provides a competitive 
advantage such as a strong brand (cfr. trade names) 
– Goodwill needs to be taken up in the balance sheet besides the 
tangible assets 
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Enhancing Comparability 
• It is often difficult to find deals closely related to 
your IP 
• The market could have changed since the 
reference deal 
• More competition could have entered the market 
• Available information can be enhanced to your 
specific case by means of a scoring system 
• The basis: evaluating your IP on various preset 
criteria in relation to or comparison with the 
same criteria for products in historical related 
deals 
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Enhancing Comparability 
• Criteria: 
– Set of criteria needs to be determined related to the IP position and 
strengths, deal type, territory, life time, advantages, etc… 
• Scale: 
– Choose a scale for the selected criteria: e.g. Likert scale, non-
numerical or Crayola® 
• Weight: 
– Not all criteria are equally important and therefore a weight should be 
given to each of the criteria used 
• Scoring: 
– Scoring is done for the new IP in comparison to perceived value of the 
criteria related to the reference deals or industry standards 
• Adapting: 
– After the scoring the numbers in the historical reference deals, or 
standards, need to be adjusted 
 34 
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Enhancing Comparability 
35 
Example: 
•Cfr. deal terms on food safety modeling software 
•Assuming we have a novel, better software and databases 
 
 
 
 
 
 
 
•The reference product as described in the deal would get a total score of 30 
•Correction factor: the score for our product divided by the score of the reference 
product, in this example the correction factor = 37/30 = 1.23 
•Correction factor can be used to determine estimated deal terms for our new IP 
Criteria Scale Weight Score 
Patent life time 
Phase of development 
Exclusivity 
Competition 
Advantage over others 
Territory 
Margins  
1       2       3       4       5 
1       2       3       4       5 
1       2       3       4       5 
1       2       3       4       5 
1       2       3       4       5 
1       2       3       4       5 
1       2       3       4       5 
2 
2 
2 
1 
1 
1 
1 
8 
10 
6 
2 
3 
4 
4 
Reference product = 3  TOTAL 37 
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Enhancing Comparability 
36 
• More reliable estimate could be obtained if we would be able to 
identify a very low end deal and a very high end deal for our related 
technology. 
• In the case we would be able to identified multiple related historical 
deals, we can assess the possible value of our new IP by clustering.  
Food Safety Software Deal Terms for novel software 
Stage Fully developed   SIMILAR 
IP Software (©), Databases, Trademark,  SIMILAR 
Territory Worldwide   SIMILAR 
Type Exclusive, for all IP and its commercialization SIMILAR 
Stage payments If sales reach €1 mio €50000 X1.23 = €61500 
If sales reach €5 mio €200000 X1.23=€246000 
Duration 10 years, afterwards all rights will go to licensee SIMILAR 
Royalties 7%  on Net Sales x 1.23= 8.6% on Net Sales 
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The “25 Percent Rule” 
• What if no closely related industrial standards or 
historical deals can be found? 
• A possible solution can be applying a general 
accepted rule of thumb 
• Goldschneider et al. defines the over 40 years old 
rule as “dividing the expected profits for the 
product or technology that incorporates the IP at 
issue in such a way that 25% is retained by the 
licensor (the seller) and that 75% goes to the 
licensee (the buyer)” 
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The “25 Percent Rule” 
38 
• New IP is assumed to be generating new sales in a specific 
business sector 
• It is possible to identify companies that are active in that 
specific sector 
• In financial statements of the company we can find: 
TURNOVER/SALES/REVENUES 
- COGS 
= GROSS MARGIN 
- Sales and marketing expenses 
- Research and development 
- General overhead and administration 
- Other expenses 
= EARNINGS/OPERATIONAL PROFIT BEFORE INTEREST AND TAXES (EBIT) 
- Interest 
- Taxes 
= EARNINGS/OPERATIONAL PROFIT AFTER INTEREST AND TAXES 
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The “25 Percent Rule” 
• For the 25 percent rule, we need the EBIT 
value 
• EBIT can be expressed as a % of the original 
revenues 
• The 25 percent rule states that a licensor 
could ask for 25% of this EBIT 
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The “25 Percent Rule” 
40 
Example: food and agricultural related in vitro diagnostics 
•The company Biomerieux is an important industrial player 
•Biomerieux is a public company (www.biomerieux.com) 
•Financial data is available, e.g. the annual report 2009 
 Value Percentage  
Net sales                                                    €1223.4 million 
Cost of sales (cfr. COGS)                      -  €563.8 million 
100% 
- 46% 
Gross profit (cfr. gross margin)              €659.6 million 
(other operating income                         €12.5 million) 
Selling and marketing expenses          - €217.1 million 
General and administration expenses- €98.7 million 
Research and development expenses- €143.0 million 
54% 
 
- 17.7% 
- 8.1% 
- 11.7% 
Total operating expenses                     - €458.8 million - 37.5% 
Operating income before non-recurring items (cfr. EBIT) 
minus other operating income           €200.8 million         
 
16.4% 
Royalty on net sales                    4.10%    (25 percent rule)  
 
Valorization of Diagnostic Innovations  
© Prof. B. Sas 2013 
The “25 Percent Rule” 
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• 25% is of course for all IP needed to get the product produced and 
sold 
• Licensees can argue that licensors should retain less than 25% 
• Licensors can argue that the licensee should get less than 75% 
• Important to compare the EBIT numbers from several players, since 
they can differ 
 
 
 
 
 
 
 
 
 *conversions are based on weighted average annual rates. 
 **calculated as 25% of the EBIT. 
 
 
Company Revenues * 
(€ millions) 
EBIT * 
(€ millions) 
As % of 
revenues 
% royalty on 
net sales ** 
Nestlé 71270 10397 14.6% 3.65% 
Unilever 39823 5020 16.6% 3.15% 
Kraft 28971 3963 13.7% 3.42% 
General Mills 10539 1894 18% 4.49% 
Grupo Bimbo 6233 645.7 10.4% 2.59% 
Heinz 7182 1078 15% 3.7% 
Cambell’s 5442 850.1 15.6% 3.9% 
   Av. 14.84% 3.56% 
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The “25 Percent Rule” 
• What about new IP on processes for the production of 
known products? 
• The 25 percent rule will not be applied on the revenues 
generated on the commercialized product 
• It will be applied on gain resulting from the proprietary 
improved production process over the old production 
process 
• Some other helpful rules of thumb: 
– Non-exclusive licenses are half or less compared to deal terms for 
exclusive licenses 
– Upfront/stage payments can be 5 to 10% of the total retained intrinsic 
value 
– Split profit for fully developed products 
– Upfront payment should minimum cover all IP related costs 
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The “FRAND Licensing Terms” 
• There was a lot of debate regarding the 25% rule, 
especially since the Uniloc ruling in which the use of 
the 25% rule was barred. 
(Uniloc vs Microsoft, CAFC, Jan 4, 2011) 
• Alternative approaches are being developed and 
proposed. 
• Fair, Reasonable And Non-Discriminatory (FRAND) 
licensing terms are based on equalizing the rates of 
return on investments made by the parties involved. 
(Granstrand et al. Les Nouvelles, 188-195, 2012) 
• Return On Investment  (ROI):  
  = C returns/I investment  
  = (gains minus investments)/investments 
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The “FRAND Licensing Terms” 
• For bilateral agreements (1 licensor and 1 licensee), the 
royalties on can be defined as: 
 
𝐿 = 𝐼𝐼
𝐼𝐼 + 𝐼𝐼 .𝜋opb 
 
With  L = royalty paid by Licensee (buyer). 
 IS = investments made by the licensor (seller). 
 IB = investments made by the licensee (buyer). 
 πopb = operating profit of the licensee (buyer). 
 
• The formula can be expanded towards multiple 
licensees and multiple licensors. 
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The “FRAND Licensing Terms” 
EXAMPLE 
• A research company invested €2 mio for the 
development of a new diagnostic. 
• The company licensed the commercialization to 
Biomerieux (with an of EBIT 16.4% of the turn-over)  
who invested €5 mio for further development. 
• According to FRAND the royalties on Net Sales could 
be: 
L  = (€2 mio / (€2mio + €5 mio)) x 16.4% on Net Sales 
 = 4.69% on Net Sales 
(versus 4.10% when the 25% rule is followed) 
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Introduction 
• Previous methods are more general, somewhat 
empirical 
• DCF method  is much more mathematical 
• Most used approach in industry to assess the 
value of IP 
• The DCF method estimates, calculates via 
discounting what the actual value of future cash 
flows would be today 
• The DCF method gives you the Net Present Value 
(NPV) 
47 
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The Cash Flow Projections 
48 
• Determine the cash flows for the different years that are part 
of the NPV calculation 
• All numbers that are given are estimations and the cash flows 
are pro forma 
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DCF Techniques 
49 
Net Present Value 
( )∑ +=
n
t t
t
d
C
0 1
•Should we do an investment of X now if we can expect cash flows Y in the future? 
 
 NPV < 0   bad investment 
 NPV = 0  profit equals the expected minimum 
 NPV > 0  profit is better than the expected minimum 
 
  
Ct = Cash flow @ year t for a total of n years 
d = discount rate   The rate that a value is decreasing in 
   time due to inflation, risk, … 
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DCF Techniques 
50 
Internal Rate of Return 
For a given NPV, determine d 
so that the NPV =0 ( )
0
0 1
=∑
+=
n
t t
t
d
C
•The IRR value is compared to a pre-set minimum i.e. the 
cut of rate of a minimum return/yield 
•If the IRR is higher the project can be accepted 
•If the IRR is lower the project is rejected 
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DCF Techniques 
51 
Pay Back Period (PP) 
•PP is the time needed for the cash inflows to cover the (initial) 
investment. 
•PP is one of the most popular alternatives to NPV. 
•Example: 
 
 
 
 
 
•The Pay Back Period Rule (PPR) is single: a particular cut-off 
period needs to be selected e.g. 3 years. 
•Discounted Pay Back Period (DPP): first discount the cash flows 
before looking at the Pay Back Period. 
Time (year) 0 1 2 3 4 
Cash out € 60000 € 0 € 0 € 0 € 0 
Cash in 0 € 10000 € 20000 € 30000 € 40000 
 Pay Back Period (PP) = 3 years 
covers 
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DCF Techniques 
52 
Basic Risk-Adjusted DCF 
Techniques 
Sensitivity analyses
•Another approach to cope with uncertainty.
•Similar: scenario analyses.
•It examines how the NPV or IRR changes related to the assumptions
made.
Expected NPV = eNPV = (NPVW x probabilityW) + (NPVE x
probabilityE) + (NPVB x probabilityB)
Σ probabilities = 1
Worst case Expected Best case
Income 
Expenses
Risk (discount rate)
Timings 
NPVW or IRRW NPVE or IRRE NPVB or IRRB
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The Cash Flow Projections 
53 
• Major drawback is the chance of error due to subjective 
estimation 
• Different risks and uncertainties associated with a multi-
stage cash flow (cfr. variable discount rates)  
 Several risk-adjusted DCF methods have been 
developed: 
– Monte Carlo methods in which the NPV calculation goes through 
multiple iterations using every time a different input value, the 
end-result being a frequency distribution of NPV 
– Decision Tree Analysis (DTA) uses a tree like graphic of decisions 
and the possible consequences, including probability expected 
values (for each branch) 
– Option Pricing Theory (OPT) methods, accounting for changing risk 
of future cash flows linked to the value of the share subject to the 
call option 
– These are more complicated and not part of this presentation 
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The percentage used for 
the discount rate can 
have a significant impact 
on the intrinsic value of 
a project (NPV) 
 
 
 
Which percentage should be used? 
3 important aspects that need to be taken in account: 
1. The inflation 
2. Alternative rates of return for investments 
3. The risk associated with the project, both technological, 
scientific and economical 
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•Income, expenses, speed (timing), risk all have an impact on the 
method e.g. NPV, IRR etc. 
•In order to have a better result in NPV one can increase sales, 
reduce cost, speed up commercialization etc. 
•Nevertheless, it is important to be as realistic as possible with 
the assumptions. 
Reduce costs 
Accelerate gains 
Increase gains 
Time 
Cash 
Flow  
+ 
-  
NPV 
IRR 
DECREASING RISK 
DECREASING d 
Reduce time of cash outflows 
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Projects can be evaluated 
on a single DCF criteria 
Projects can be evaluated 
on multiple DCF criteria 
NPV 
IRR 
Project 1 
Project 2 
Hurdle Rate 
€ 
m
ill
io
n 
(%) 
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Overview  
• The Agricultural and Environmental Diagnostic Market 
 
• Intellectual Property (IP) 
 
• Valorization of IP 
 
• Industrial Standards 
 
• Discounted Cash Flow (DCF) Methods 
 
• Dividing the Intrinsic Value 
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Dividing the Intrinsic Value 
How can the intrinsic value of the new IP be divided between the 
licensor (the seller) and the licensee (the buyer): 
 
1.Excess earnings concept 
• If a licensee uses a discount rate where both his expected 
return on the investment as well as the risk related to the 
project is incorporated, than all of the “positive value” of the 
calculated NPV need to go to the licensor 
- The licensee buys the patent and pays a lump-sum equal to 
the NPV value 
- NPV value is spread via upfront payments, stage payments 
and royalties 
 
58 
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2. The 25 percent rule 
• If seller and buyer agree that a discount rate will be 
used that provides only the appropriate present 
values of all the future benefits, given the risk of the 
project, than the resulting NPV value should be 
divided in a way that reflects the contribution of each 
party, e.g. using the 25 percent rule 
 • Building an excel model together with the “goal seek” 
function or “scenario manager” function can be very 
helpful 
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• This 25% of the NPV can be paid as a lump-
sum or spread over time via upfront, stage 
and royalty payments 
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3. The FRAND Licensing Terms 
• Similar to the 25% rule for dividing the value (NPV) of 
a project, also the FRAND approach can be used. 
• In this case the NPV needs to be divided taking in 
account the investments made by each party. 
• Also in this case an excel model together with the 
“goal seek” function or “scenario manager” function 
can be very helpful 
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(in € MIO) 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Number of flocks of chickens 66,00 66,73 67,46 68,20 68,95 69,71 70,48 71,25 72,04 72,83 73,63 74,44 75,26 76,09 76,92 77,77 78,63 79,49 80,36 81,25 82,14
Estimated maximum tests 0,66 0,67 0,67 0,68 0,69 0,70 0,70 0,71 0,72 0,73 0,74 0,74 0,75 0,76 0,77 0,78 0,79 0,79 0,80 0,81 0,82
Estimated top annual sales € 40 € 40 € 40 € 41 € 41 € 42 € 42 € 43 € 43 € 44 € 44 € 45 € 45 € 46 € 46 € 47 € 47 € 48 € 48 € 49 € 49
Turnover € 0 € 0 € 0 € 0 € 4 € 10 € 21 € 34 € 43 € 44 € 44 € 45 € 45 € 36 € 29 € 23 € 18 € 15 € 12 € 9 € 8
Initial R&D costs € 0,60 € 0,60 € 0,60 € 0,60 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0 € 0
Initial Patent Costs € 0,00 € 0,02 € 0,02 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00
COGS € 0 € 0 € 0 € 0 € 2 € 5 € 10 € 16 € 20 € 20 € 20 € 20 € 21 € 16 € 13 € 11 € 8 € 7 € 5 € 4 € 3
Sales & Marketing € 0 € 0 € 0 € 0 € 1 € 2 € 4 € 6 € 7 € 7 € 7 € 8 € 8 € 6 € 5 € 4 € 3 € 2 € 2 € 2 € 1
Gen & Admin € 0 € 0 € 0 € 0 € 0 € 1 € 2 € 4 € 5 € 5 € 5 € 5 € 5 € 4 € 3 € 3 € 2 € 2 € 1 € 1 € 1
R&D € 0 € 0 € 0 € 0 € 0 € 1 € 1 € 2 € 3 € 3 € 3 € 3 € 3 € 2 € 2 € 1 € 1 € 1 € 1 € 1 € 0
Net cash -€ 0,60 -€ 0,62 -€ 0,62 -€ 0,60 € 0,85 € 2,14 € 4,32 € 6,99 € 8,84 € 8,94 € 9,03 € 9,13 € 9,23 € 7,39 € 5,91 € 4,73 € 3,78 € 3,03 € 2,42 € 1,94 € 1,55
Discounted net cash -€ 0,60 -€ 0,56 -€ 0,51 -€ 0,45 € 0,58 € 1,33 € 2,44 € 3,59 € 4,12 € 3,79 € 3,48 € 3,20 € 2,94 € 2,14 € 1,56 € 1,13 € 0,82 € 0,60 € 0,44 € 0,32 € 0,23
Acc. disc. net cash -€ 0,60 -€ 1,16 -€ 1,68 -€ 2,13 -€ 1,55 -€ 0,22 € 2,22 € 5,81 € 9,93 € 13,72 € 17,20 € 20,41 € 23,35 € 25,49 € 27,04 € 28,18 € 29,00 € 29,60 € 30,03 € 30,35 € 30,58
NPV (€ MIO) € 31
IRR 60%
Discount rate 10,00%
probability of success 40%
pNPV (€ MIO) € 12
pIRR 24%
Example 
• Financial Valuation of a new diagnostic(s) for the 
GI health in chickens, including NE 
• Used to compile a dossier for funding 
• With involvment of the industry 
• Forms a base for further discussions regarding 
commercial partnerships. 
number of chickens in 2013 (MIO) 66
annual growth 1,10%
rate of use 1,00%
price per test € 60
Initial R&D cost/year € 0,60
Initial patent cost/year € 0,02
COGS 45,56% as a % of the turn-over
Sales & Marketing 16,87% as a % of the turn-over
Gen & Admin 10,86% as a % of the turn-over
Continuing R&D 6,26% as a % of the turn-over
First year after Launch 10,00% of the estimated Top Annual Sales
Second year after Launch 25,00% of the estimated Top Annual Sales
Third year after Launch 50,00% of the estimated Top Annual Sales
Fourth year after Launch 80,00% of the estimated Top Annual Sales
Fifth till ninth year after Launch 100,00% of the estimated Top Annual Sales
Decrease per year after ninth year 20,00% of the estimated Top Annual Sales
ASSUMPTIONS
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What Deal Terms could we propose: 
• 10% of 25% of the risk adjusted NPV as upfront payment = €0.3 mio 
• The remaining part of the 25% of the NPV as royalties on Net Sales 
• Set-up of model in EXCEL 
• Use of “Goal Seek Function” 
 5% Royalties on Net Sales gives  80% of the Project Value to Licensee 
     20% of the Project Value to Licensor 
LICENSEE (in € MIO) 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Turnover € 0 € 0 € 0 € 0 € 4 € 10 € 21 € 34 € 43 € 44 € 44 € 45 € 45 € 36 € 29 € 23 € 18 € 15 € 12 € 9 € 8
Stage payments to Licensor € 0,30
Royalties to Licensor € 0 € 0 € 0 € 0 € 0 € 1 € 1 € 2 € 2 € 2 € 2 € 2 € 2 € 2 € 1 € 1 € 1 € 1 € 1 € 0 € 0
COGS € 0 € 0 € 0 € 0 € 2 € 5 € 10 € 16 € 20 € 20 € 20 € 20 € 21 € 16 € 13 € 11 € 8 € 7 € 5 € 4 € 3
Sales & Marketing € 0 € 0 € 0 € 0 € 1 € 2 € 4 € 6 € 7 € 7 € 7 € 8 € 8 € 6 € 5 € 4 € 3 € 2 € 2 € 2 € 1
Gen & Admin € 0 € 0 € 0 € 0 € 0 € 1 € 2 € 4 € 5 € 5 € 5 € 5 € 5 € 4 € 3 € 3 € 2 € 2 € 1 € 1 € 1
R&D € 0 € 0 € 0 € 0 € 0 € 1 € 1 € 2 € 3 € 3 € 3 € 3 € 3 € 2 € 2 € 1 € 1 € 1 € 1 € 1 € 0
Net cash € 0 € 0 € 0 € 0 € 1 € 2 € 3 € 5 € 7 € 7 € 7 € 7 € 7 € 6 € 4 € 4 € 3 € 2 € 2 € 1 € 1
Discounted net cash € 0 € 0 € 0 € 0 € 0 € 1 € 2 € 3 € 3 € 3 € 3 € 2 € 2 € 2 € 1 € 1 € 1 € 0 € 0 € 0 € 0
Acc. disc. net cash € 0 € 0 € 0 € 0 € 0 € 1 € 3 € 6 € 9 € 12 € 14 € 17 € 19 € 21 € 22 € 23 € 23 € 24 € 24 € 24 € 24
LICENSOR (in € MIO) 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Stage Payments € 0,00 € 0,00 € 0,30 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00
Royalties € 0,00 € 0,00 € 0,00 € 0,00 € 0,21 € 0,52 € 1,06 € 1,71 € 2,16 € 2,18 € 2,21 € 2,23 € 2,26 € 1,81 € 1,44 € 1,16 € 0,92 € 0,74 € 0,59 € 0,47 € 0,38
Initial R&D costs € 0,60 € 0,60 € 0,60 € 0,60 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00
Initial patent costs € 0,00 € 0,02 € 0,02 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 0,00
Net cash -€ 0,60 -€ 0,62 -€ 0,32 -€ 0,60 € 0,21 € 0,52 € 1,06 € 1,71 € 2,16 € 2,18 € 2,21 € 2,23 € 2,26 € 1,81 € 1,44 € 1,16 € 0,92 € 0,74 € 0,59 € 0,47 € 0,38
Discounted net cash -€ 0,60 -€ 0,56 -€ 0,26 -€ 0,45 € 0,14 € 0,32 € 0,60 € 0,88 € 1,01 € 0,93 € 0,85 € 0,78 € 0,72 € 0,52 € 0,38 € 0,28 € 0,20 € 0,15 € 0,11 € 0,08 € 0,06
Acc. disc. net cash -€ 0,60 -€ 1,16 -€ 1,43 -€ 1,88 -€ 1,74 -€ 1,41 -€ 0,82 € 0,06 € 1,07 € 2,00 € 2,85 € 3,63 € 4,35 € 4,87 € 5,25 € 5,53 € 5,73 € 5,88 € 5,98 € 6,06 € 6,12
Stage Payments (mio) € 0,30 € 24 79,99%
Royalty on Net Sales 5% € 6,12 20,01%
NPV Licensee (mio)
NPV Licensor (mio)
which is of the Project Value (total NPV):
which is of the Project Value (total NPV):
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